Compare Taskus Inc (TASK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs TransMedics Group Inc — how do they compare? Taskus Inc trades at $6.67 (market cap $632.18M), while TransMedics Group Inc trades at $87.63 (market cap $3.10B). The key difference: TransMedics Group Inc is far larger — about 4.9× Taskus Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| TASK | TMDX | |
|---|---|---|
Market Cap | $632.18M | $3.10B |
Sector | Technology | Technology |
52-Week High | $18.21 | $150.42 |
52-Week Low | $4.57 | $61.99 |
Enterprise Value | $998.23M | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $7.10, down 2.74% today but maintains strong fundamentals with a P/E of 5.94 and robust profitability. The stock shows bullish technical signals with support at $7 and resistance at $8. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected, while revenue grew 5% year-over-year to $308.9 million, driven by AI Services growth.
The outlook remains positive with analyst consensus at Buy (54.55%) and $8.00 price target, representing 12.7% upside. Key risks include client concentration and competitive pressures in digital services. Strong cash flow generation and improving debt-to-asset ratio (22.96% in 2025) support continued growth potential.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
